[
    {
        "content": "* Q3 revenue $142.8 million versus I/B/E/S view $132.8 million",
        "date": "11072017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro reports Q3 loss per share $0.47 "
    },
    {
        "content": "Oct 25 Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.",
        "date": "10252017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "FDA approves intravenous version of Tesaro drug for chemotherapy nausea "
    },
    {
        "content": "* Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy",
        "date": "10262017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea  vomiting associated with chemotherapy "
    },
    {
        "content": "* dgap-news: evotec and tesaro enter strategic partnership to discover novel immuno-oncology agents",
        "date": "10262017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "BRIEF-Evotec  Tesaro enter partnership on novel immuno-oncology agents "
    },
    {
        "content": "Sept 15 A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug  niraparib  for the treatment of recurrent ovarian cancer.",
        "date": "09152017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "Tesaro's ovarian cancer drug gets EU agency backing "
    },
    {
        "content": "* Q2 earnings per share view $-2.49 -- Thomson Reuters I/B/E/S",
        "date": "08082017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro Inc Q2 loss per share $2.82 "
    },
    {
        "content": "* Tesaro Inc sale process seen unlikely to result in a deal - CNBC  citing sources Further company coverage:",
        "date": "07132017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro sale process seen unlikely to result in a deal - CNBC "
    },
    {
        "content": "* Rival Tesaro's shares slip 3 pct (Adds analyst comment; updates shares)",
        "date": "06192017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "UPDATE 4-Clovis's ovarian cancer drug set for label expansion  shares soar "
    },
    {
        "content": "* Tesaro shares soar more than 10 percent after DJ reports co is exploring a sale  asked for initial bids - CNBC  citing DJ Source text: http://on.wsj.com/2rc8WqL Further company coverage:",
        "date": "05312017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "RPT-BRIEF-Tesaro Inc is exploring a sale  asked for initial bids - CNBC  citing DJ "
    },
    {
        "content": "* Tesaro shares soar more than 10 percent after DJ reports co is exploring a sale  asked for initial bids - CNBC  citing DJ Further company coverage:",
        "date": "05312017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro Inc is exploring a sale  asked for initial bids - CNBC "
    },
    {
        "content": "* Q1 earnings per share view $-2.24 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:",
        "date": "05092017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro reports Q1 loss per share $2.55 "
    },
    {
        "content": "* TESARO announces submission of investigational new drug application for anti-lag antibody tsr-033 to the u.s. Fda",
        "date": "05012017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-TESARO submits investigational new drug application for TSR-033 to U.S. FDA "
    },
    {
        "content": "* Tesaro initiates registrational development program  for anti-pd-1 antibody tsr-042",
        "date": "04272017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro initiates registrational development program for anti-pd-1 antibody TSR-042 "
    },
    {
        "content": "* Tesaro announces approval of Varuby\u00ae (oral rolapitant tablets) by European Commission",
        "date": "04262017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro announces approval of Varuby by European Commission "
    },
    {
        "content": "* US Bioservices says has been selected by Tesaro  Inc as a specialty pharmacy partner for Zejula Source text for Eikon: Further company coverage:",
        "date": "04192017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro selects US Bioservices as specialty pharmacy partner for Zejula "
    },
    {
        "content": "* Diplomat Pharmacy Inc says  will dispense zejula to treat recurrent epithelial ovarian  fallopian tube  or primary peritoneal cancer",
        "date": "04192017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "BRIEF-Diplomat Pharmacy says will dispense Tesaro's cancer drug "
    },
    {
        "content": "* TESARO announces availability of zejula\u2122 (niraparib) for patients with recurrent ovarian cancer in the U.S.",
        "date": "04192017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "BRIEF-TESARO announces availability of ovarian cancer drug in U.S. "
    },
    {
        "content": "* CEO Leon Moulder Jr's 2016 total compensation was $5.7 million versus $5.5 million in 2015 - SEC filing Source text: (http://bit.ly/2oMgYGz) Further company coverage:",
        "date": "04072017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro CEO 2016 total compensation was $5.7 mln "
    },
    {
        "content": "March 27 The U.S. Food and Drug Administration on Monday approved Tesaro Inc's key drug  niraparib  for the treatment of recurrent ovarian cancer.",
        "date": "03272017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "UPDATE 1-FDA approves Tesaro's ovarian cancer drug "
    },
    {
        "content": "* U.S. FDA - FDA granted the application fast track  priority review and breakthrough therapy designations",
        "date": "03272017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "BRIEF-FDA approves Tesaro's ovarian cancer drug "
    },
    {
        "content": "* Tesaro announces expanded development program for Niraparib focused on the treatment of front-line metastatic ovarian and lung cancers and metastatic breast cancer",
        "date": "03272017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro to expand development program for Niraparib drug "
    },
    {
        "content": "March 27 The U.S. Food and Drug Administration on Monday approved Tesaro Inc's drug  niraparib  for the treatment of recurrent ovarian cancer.",
        "date": "03272017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "FDA approves Tesaro's ovarian cancer drug "
    },
    {
        "content": "* TESARO announces U.S. FDA approval of zejula\u2122 (niraparib) for women with recurrent ovarian cancer",
        "date": "03272017",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "BRIEF-TESARO announces U.S. FDA approval of zejula for women with recurrent ovarian cancer "
    },
    {
        "content": "* Tesaro announces presentation of niraparib phase 3 ENGOT-OV16/NOVA trial secondary endpoint results during SGO",
        "date": "03132017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro reports Niraparib phase 3 ENGOT-OV16/NOVA trial secondary endpoint results "
    },
    {
        "content": "U.S. biopharmaceutical company Tesaro Inc  is discussing its options with investment banks after receiving acquisition interest from several drugmakers  according to people familiar with the matter.",
        "date": "02082017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "Exclusive: Cancer drugmaker Tesaro attracts takeover interest - sources "
    },
    {
        "content": "* Tesaro announces opening of niraparib expanded access program for u.s. Patients with ovarian cancer",
        "date": "01172017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro announces opening of Niraparib expanded access program for U.S. patients with ovarian cancer "
    },
    {
        "content": "* Tesaro receives complete response letter for Rolapitant IV from U.S. FDA",
        "date": "01122017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro receives complete response letter for Rolapitant IV from U.S. FDA "
    },
    {
        "content": "* Sees total number of units of Varubi sold by company in quarter ended December 31  2016 were approximately 9 165 units  Source text - (http://bit.ly/2iZWOWx) Further company coverage:",
        "date": "01092017",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro expects to have sold about 9 165 Varubi units in quarter ended Dec. 31 "
    },
    {
        "content": "* Priced an underwritten public offering of an aggregate of 1.75 million shares of common stock at offering price to public of $135.00/share",
        "date": "11152016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro announces pricing of public offering of common stock "
    },
    {
        "content": "* Tesaro Inc says  pre-launch planning ongoing to support four potential product launches in 2017 across U.S. and Europe",
        "date": "11032016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro announces third-quarter 2016 operating results "
    },
    {
        "content": "* Tesaro announces submission of niraparib new drug application for platinum-sensitive  recurrent ovarian cancer  Source text for Eikon:  Further company coverage:",
        "date": "11012016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro announces submission of niraparib new drug application "
    },
    {
        "content": "* Tesaro and zai lab announce collaboration  development and license agreement",
        "date": "09292016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro and Zai Lab announce collaboration  development and license agreement "
    },
    {
        "content": "* Tesaro receives FDA fast track designation for niraparib and initiates rolling NDA submission",
        "date": "09122016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro gets FDA fast track designation for niraparib "
    },
    {
        "content": "* Q2 loss per share $1.28  Source text for Eikon: (http://bit.ly/2axcOJk) Further company coverage:",
        "date": "08042016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro Q2 loss per share $1.28 "
    },
    {
        "content": "* Engot and Tesaro partnership generates positive data from engot-ov16/nova phase 3 trial",
        "date": "07082016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Engot and Tesaro present positive data from ovarian cancer drug "
    },
    {
        "content": "Tesaro Inc said its experimental ovarian cancer drug niraparib met the main goal of prolonging survival in patients  without the disease worsening  in a late-stage trial  sending its shares to a record high.",
        "date": "06292016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "Tesaro's ovarian cancer drug study succeeds  shares soar "
    },
    {
        "content": "* Shares of rival Clovis Oncology also rise   (Adds details; analyst comments)",
        "date": "06292016",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "UPDATE 2-Tesaro's ovarian cancer drug study succeeds  shares soar "
    },
    {
        "content": "June 29 Tesaro Inc said its ovarian cancer drug met the main goal of prolonging survival in patients  without the disease worsening  in a late-stage trial  sending its shares up 69 percent in premarket trading.",
        "date": "06292016",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "Tesaro's ovarian cancer drug shows benefit in late-stage trial "
    },
    {
        "content": "* Says files for mixed shelf offering with the U.S. SEC; size undisclosed - SEC filing  Source: (http://1.usa.gov/295fkJh ) Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",
        "date": "06302016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro files for mixed shelf offering - SEC filing "
    },
    {
        "content": "* Tesaro Inc says has commenced an underwritten public offering of $300 million of its common stock  Source text for Eikon:  Further company coverage:    )",
        "date": "06302016",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro Inc says commenced an underwritten public offering of $300 mln of its common stock "
    },
    {
        "content": "* Steven Cohen reports 5.3 percent passive stake in Tesaro Inc as of May 9 - Sec filing  Source text: http://1.usa.gov/1WmJHft Further company coverage:",
        "date": "05102016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Steven Cohen reports 5.3 percent passive stake in Tesaro Inc "
    },
    {
        "content": "* Chief executive officer Leon Moulder total 2015 compensation $5.5 million versus $3.6 million in 2014",
        "date": "04082016",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "BRIEF-Tesaro - CEO total 2015 compensation "
    },
    {
        "content": "Sept 2 The U.S. Food and Drug Administration approved Tesaro Inc's treatment for chemotherapy-induced nausea and vomiting in adults  the company said on Wednesday.",
        "date": "09022015",
        "name": "TESARO Inc",
        "news_type": "topStory",
        "symbol": "TSRO",
        "title": "UPDATE 1-FDA approves Tesaro's drug for chemotherapy-induced nausea "
    },
    {
        "content": "Sept 2 The U.S. Food and Drug Administration approved Tesaro Inc's treatment for chemotherapy-induced nausea and vomiting in adults  the company said on Wednesday.",
        "date": "09022015",
        "name": "TESARO Inc",
        "news_type": "normal",
        "symbol": "TSRO",
        "title": "FDA approves Tesaro's treatment for chemotherapy-induced nausea "
    }
]